Wolff Wiese Magana’s 10x Genomics TXG Stock Holding History

Wolff Wiese Magana’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-188	Closed	-$5K	–	972
2022 Q3	$5K	Sell	188 -99	-34%	-$3.77K	﹤0.01%	626
2022 Q2	$13K	Hold	287	–	–	0.01%	495
2022 Q1	$22K	Buy	287 +91	+46%	+$7.96K	0.01%	409
2021 Q4	$29K	Buy	+196	New	+$30K	0.02%	361

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wolff Wiese Magana's TXG Position: Q4 2022 in Review

Wolff Wiese Magana sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 188 shares — an estimated $5K sold.

Wolff Wiese Magana first reported a position in TXG in Q4 2021 and held it in 4 quarters. The position peaked at $29K in Q4 2021. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

Wolff Wiese Magana reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
Wolff Wiese Magana sold 188 10x Genomics shares in Q4 2022, an estimated $5K.
Wolff Wiese Magana first reported a position in 10x Genomics in Q4 2021 and held it in 4 quarters.
Wolff Wiese Magana's 10x Genomics position peaked at $29K in Q4 2021.
268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on Wolff Wiese Magana's 13F filing for Q4 2022, filed 9 Feb 2023.